...an independent member of its board; Lonberg was formerly scientific director at GenPhar Inc. and Medarex Inc....

...with first-in-class molecules, including the 2001 deal for Erbitux cetuximab and the 2009 acquisition of Medarex Inc....
...Co-development and co-commercialization deal for first-in-class Erbitux cetuximab from ImClone Systems Inc. 7/22/09 - Acquired Medarex Inc....
...of the recession, BMS’s market cap hovered around $40 billion. Its July 2009 acquisition of Medarex Inc....

...toxicities in standard preclinical models, he said. Beatty noted that a preclinical safety report on Medarex Inc.’s...
...monkey studies, yet failed to detect any notable clinical or pathological toxicity. BMS partnered with Medarex...

...to co-develop anifrolumab, which was generated using Medarex’s UltiMAb technology. Bristol-Myers Squibb Co. (NYSE:BMY) acquired Medarex...

...to co-develop anifrolumab, which was generated using Medarex’s UltiMAb technology. Bristol-Myers Squibb Co. (NYSE:BMY) acquired Medarex...

...and moderately to severely active Crohn's disease (CD). Stelara was generated using UltiMAb technology from Medarex Inc....

...Mediterranean fever (FMF). Ilaris is a human anti-IL-1 beta mAb that uses UltiMAb technology from Medarex Inc....

...moderately to severely active Crohn’s disease (CD). J&J’s Stelara was generated using UltiMAb technology from Medarex Inc....

...arthritis. Sales of the drug were $283 million in 2016. Ilaris uses UltiMAb technology from Medarex Inc....

...and gouty arthritis. Ilaris is a human anti-IL-1 beta mAb that uses UltiMAb technology from Medarex Inc....